ANI Pharmaceuticals
ANIP
ANIP
175 hedge funds and large institutions have $369M invested in ANI Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 50 increasing their positions, 55 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
175
Holders Change
+12
Holders Change %
+7.36%
% of All Funds
4.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
50
Reduced
55
Closed
15
Calls
$8.14M
Puts
$11.4M
Net Calls
-$3.23M
Net Calls Change
+$15.1M
Top Buyers
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$16.3M |
| 2 |
Goldman Sachs
New York
|
+$2.74M |
| 3 |
Millennium Management
New York
|
+$2.58M |
| 4 |
AIA
Avalon Investment & Advisory
Houston,
Texas
|
+$2.57M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$2.49M |
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$14.5M |
| 2 |
ICOM
Investment Counselors of Maryland
Baltimore,
Maryland
|
-$3.96M |
| 3 |
Bank of New York Mellon
New York
|
-$3.62M |
| 4 |
Renaissance Technologies
New York
|
-$3.35M |
| 5 |
NC
Nexthera Capital
New York
|
-$2.7M |
